Pharmacogenomics testing in a community pharmacy

Patient perceptions and willingness-to-pay

Mara L. Gibson, Kenneth Hohmeier, Cindy T. Smith

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: To determine patient knowledge, interest and willingness-to-pay for pharmacogenomics testing in a community pharmacy. Patients & methods: The link to a cross-sectional, anonymous online survey was distributed to a convenience sample of patients. The contingent valuation method was used to assess willingness-to-pay. Results: Twenty seven surveys were completed. Eighty one percent of patients were interested in the service, but patients felt that they would be more likely to use the service if insurance covered the cost. Conclusion: Patients indicated interest in a pharmacogenomics test, but varying levels of willingness-to-pay. Patients may not be able to connect the benefits of testing to their health, justifying further patient education in order to increase the viability of pharmacogenomics testing as a pharmacy service.

Original languageEnglish (US)
Pages (from-to)227-233
Number of pages7
JournalPharmacogenomics
Volume18
Issue number3
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Pharmacies
Pharmaceutical Services
Pharmacogenetics
Patient Education
Pharmacogenomic Testing
Insurance
Costs and Cost Analysis
Health

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Pharmacogenomics testing in a community pharmacy : Patient perceptions and willingness-to-pay. / Gibson, Mara L.; Hohmeier, Kenneth; Smith, Cindy T.

In: Pharmacogenomics, Vol. 18, No. 3, 01.02.2017, p. 227-233.

Research output: Contribution to journalArticle

@article{4dc0c2e7886f40fb83e82263cbbc9892,
title = "Pharmacogenomics testing in a community pharmacy: Patient perceptions and willingness-to-pay",
abstract = "Aim: To determine patient knowledge, interest and willingness-to-pay for pharmacogenomics testing in a community pharmacy. Patients & methods: The link to a cross-sectional, anonymous online survey was distributed to a convenience sample of patients. The contingent valuation method was used to assess willingness-to-pay. Results: Twenty seven surveys were completed. Eighty one percent of patients were interested in the service, but patients felt that they would be more likely to use the service if insurance covered the cost. Conclusion: Patients indicated interest in a pharmacogenomics test, but varying levels of willingness-to-pay. Patients may not be able to connect the benefits of testing to their health, justifying further patient education in order to increase the viability of pharmacogenomics testing as a pharmacy service.",
author = "Gibson, {Mara L.} and Kenneth Hohmeier and Smith, {Cindy T.}",
year = "2017",
month = "2",
day = "1",
doi = "10.2217/pgs-2016-0161",
language = "English (US)",
volume = "18",
pages = "227--233",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Pharmacogenomics testing in a community pharmacy

T2 - Patient perceptions and willingness-to-pay

AU - Gibson, Mara L.

AU - Hohmeier, Kenneth

AU - Smith, Cindy T.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Aim: To determine patient knowledge, interest and willingness-to-pay for pharmacogenomics testing in a community pharmacy. Patients & methods: The link to a cross-sectional, anonymous online survey was distributed to a convenience sample of patients. The contingent valuation method was used to assess willingness-to-pay. Results: Twenty seven surveys were completed. Eighty one percent of patients were interested in the service, but patients felt that they would be more likely to use the service if insurance covered the cost. Conclusion: Patients indicated interest in a pharmacogenomics test, but varying levels of willingness-to-pay. Patients may not be able to connect the benefits of testing to their health, justifying further patient education in order to increase the viability of pharmacogenomics testing as a pharmacy service.

AB - Aim: To determine patient knowledge, interest and willingness-to-pay for pharmacogenomics testing in a community pharmacy. Patients & methods: The link to a cross-sectional, anonymous online survey was distributed to a convenience sample of patients. The contingent valuation method was used to assess willingness-to-pay. Results: Twenty seven surveys were completed. Eighty one percent of patients were interested in the service, but patients felt that they would be more likely to use the service if insurance covered the cost. Conclusion: Patients indicated interest in a pharmacogenomics test, but varying levels of willingness-to-pay. Patients may not be able to connect the benefits of testing to their health, justifying further patient education in order to increase the viability of pharmacogenomics testing as a pharmacy service.

UR - http://www.scopus.com/inward/record.url?scp=85011082491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011082491&partnerID=8YFLogxK

U2 - 10.2217/pgs-2016-0161

DO - 10.2217/pgs-2016-0161

M3 - Article

VL - 18

SP - 227

EP - 233

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 3

ER -